"These numbers underline the staggering challenge the world will face in the future in terms of numbers of people who are obese, or have Type-2 diabetes, or both. As well as the medical challenges these people will face, the costs to countries' health systems will be enormous," said Alan Moses, Chief Medical Officer at the Novo Nordisk -- a Denmark-based healthcare company.